CancerDrs

Multiple Myeloma clinical trials in Delaware

7 actively recruiting multiple myeloma trials at 7 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full multiple myeloma transparency page →

Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Delaware:
  • Beebe Medical Center — Lewes, Delaware
  • Beebe South Coastal Health Campus — Millville, Delaware
  • Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
  • Helen F Graham Cancer Center — Newark, Delaware
  • Medical Oncology Hematology Consultants PA — Newark, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Delaware:
  • ChristianaCare Helen F Graham Cancer Center and Research Institute — Newark, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Delaware:
  • Medical Oncology Hematology Consultants, PA — Newark, Delaware
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …

Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Delaware:
  • Christiana Care — Newark, Delaware
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, a…

Sponsor: AbbVie
NCT ID: NCT05650632
Sites in Delaware:
  • Medical Oncology Hematology Consultants /ID# 268560 — Newark, Delaware
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Delaware:
  • Nemours - Alfred I. duPont Hospital for Children — Brandywine, Delaware
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25